Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Cardiff Oncology Inc (NASDAQ: CRDF) closed the day trading at $2.47 up 3.78% from the previous closing price of $2.38. In other words, the price has increased by $3.78 from its previous closing price. On the day, 1.98 million shares were traded. CRDF stock price reached its highest trading level at $2.5599 during the session, while it also had its lowest trading level at $2.36.
Ratios:
For a better understanding of CRDF, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.08 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
On December 08, 2021, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $19.Robert W. Baird initiated its Outperform rating on December 08, 2021, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 17 ’24 when Levine James E. bought 2,752 shares for $5.42 per share. The transaction valued at 14,905 led to the insider holds 65,316 shares of the business.
Levine James E. bought 2,400 shares of CRDF for $12,000 on Dec 18 ’24. The Chief Financial Officer now owns 67,716 shares after completing the transaction at $5.00 per share. On Dec 16 ’24, another insider, Levine James E., who serves as the Chief Financial Officer of the company, bought 2,564 shares for $3.83 each. As a result, the insider paid 9,820 and bolstered with 62,564 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 164315024 and an Enterprise Value of 74092008. For the stock, the TTM Price-to-Sale (P/S) ratio is 241.62 while its Price-to-Book (P/B) ratio in mrq is 1.98. Its current Enterprise Value per Revenue stands at 108.48 whereas that against EBITDA is -1.536.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.88, which has changed by -0.532197 over the last 52 weeks, in comparison to a change of 0.059571505 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $5.96, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is -35.42%, while the 200-Day Moving Average is calculated to be -20.29%.
Shares Statistics:
Over the past 3-months, CRDF traded about 1.16M shares per day on average, while over the past 10 days, CRDF traded about 1737060 shares per day. A total of 66.52M shares are outstanding, with a floating share count of 59.79M. Insiders hold about 10.13% of the company’s shares, while institutions hold 34.43% stake in the company. Shares short for CRDF as of 1743379200 were 14812856 with a Short Ratio of 12.73, compared to 1740700800 on 11382589. Therefore, it implies a Short% of Shares Outstanding of 14812856 and a Short% of Float of 22.700001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
